Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Period	Debt/Equity
2021-12-31	0.33
2022-12-31	0.46
2023-12-31	0.52
2024-12-31	0.92

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNA	$6.87	+0.73%	0.56M
3
4
5

Ginkgo Bioworks Holdings Inc. Class A (DNA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Ginkgo Bioworks Holdings Inc. Class A Data in Excel

More DNA Financial Data